WASHINGTON, Oct 7 (Reuters) - Pfizer Inc's new
vaccine for children aged five to 11 could be ready as early as
November pending approval from federal regulatory health
agencies, White House COVID-19 response coordinator Jeffrey
Zients said on Thursday.
The Food and Drug Administration has scheduled time to
review the Pfizer/BionNTech application for emergency
use with its advisory panel at the end of October, to be
followed by recommendations from the Centers for Disease Control
and Prevention, Zients told CNN.
(Reporting by Doina Chiacu; Editing by Susan Heavey)